



PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet 1 of 4

<i>Complete if Known</i>	
Application Number	10/585,695
Filing Date	July 10, 2006,
First Named Inventor	Hermona SOREQ et al
Art Unit	Unknown
Examiner Name	Unknown

Attorney Docket Number 30394

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional)

<sup>2</sup> See Kind Code of USPTO Patent Document.

2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Applicant is to place a check mark here if English language translation is attached  
This collection of information is required by 37 CFR 1.97 and 1.98. The information

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/585,695
Filing Date	July 10, 2006,
First Named Inventor	Hermona SOREQ et al
Group Art Unit	Unknown
Examiner Name	Unknown

Sheet 2 Of 4 Attorney Docket Number 30394

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	7	Abbate et al. "Pathophysiologic Role of Myocardial Apoptosis in Post-Infarction Left Ventricular Remodeling", Journal of Cellular Physiology, 193(2): 145-153, 2002. Abstract.	
	8	Abbate et al. "Persistent Infarct-Related Artery Occlusion Is Associated With An Increased Myocardial Apoptosis at Postmortem Examination in Humans Late After An Acute Myocardial Infarction", Circulation, 106: 1051-1054, 2002.	
	9	Askari et al. "Effect of Stromal-Cell-Derived Factor 1 on Stem-Cell Homing and Tissue Regeneration in Ischaemic Cardiomyopathy", The Lancet, 362(9385): 697-703, 2003.	
	10	Braunwald "Myocardial Reperfusion, Limitation of Infarct Size, Reduction of Left Ventricular Dysfunction, and Improved Survival", Circulation, 79: 441-444, 1989.	
	11	Broxmeyer et al. "Stromal Cell-Derived Factor-1/CXCL12 Directly Enhances Survival/Antiapoptosis of Myeloid Progenitor Cells Through CXCR4 and Gαi Proteins and Enhances Engraftment of Competitive, Repopulating Stem Cells", Journal of Leukocyte Biology, 73(5): 630-638, 2003.	
	12	Etzion et al. "Myocardial Regeneration: Present and Future Trends", American Journal of Cardiovascular Drugs, 1(4): 233-244, 2001. Abstract.	
	13	Hale et al. "Left Ventricular Topographic Alterations in the Completely Healed Rat Infarct Caused by Early and Late Coronary Artery Reperfusion", American Heart Journal, 116(6 Pt.1): 1508-1513, 1988. Abstract.	
	14	Kelley et al. "Restraining Infarct Expansion Preserves Left Ventricular Geometry and Function After Acute Anteroapical Infarction", Circulation, 99(1): 135-142, 1999.	
	15	Kollet et al. "Rapid and Efficient Homing of Human CD34+CD38-/LowCXCR4+ Stem and Progenitor Cells to the Bone Marrow and Spleen of NOD/SCID and NOD/SCID/B2mNull Mice", Blood, 97(10): 3283-3291, 2001.	
	16	Lamas et al. "Clinical Significance of Mitral Regurgitation After Acute Myocardial Infarction", Circulation, 96(3): 827-833, 1997.	
	17	Lapidot et al. "Current Understanding of Stem Cell Mobilization: The Roles of Chemokines, Proteolytic Enzymes, Adhesion Molecules, Cytokines, and Stromal Cells", Experimental Hematology, 30: 973-981, 2002.	
	18	Lembcke et al. "Passive External Cardiac Constraint Improves Segmental Left Ventricular Wall Motion and Reduces Akinetic Area in Patients With Non-Ischemic Dilated Cardiomyopathy", European Journal of Cardio-Thoracic Surgery, 25: 84-90, 2004. Abstract.	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/585,695
				Filing Date	July 10, 2006,
				First Named Inventor	Hermona SOREQ et al
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	3	Of	4	Attorney Docket Number	30394
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	19	Lim et al. "Microencapsulated Islets as Bioartificial Endocrine Pancreas", Science, 210(4472): 908-910, 1980. Abstract.			
	20	Litwin et al. "Serial Echocardiographic Assessment of Left Ventricular Geometry and Function After Large Myocardial Infarction in the Rat", Circulation, 89(1): 345-354, 1994.			
	21	Mann "Mechanisms and Models in Heart Failure: A Combinatorial Approach", Circulation, 100(9): 999-1008, 1999.			
	22	Pillarisetti et al. "Cloning and Relative Expression Analysis of Rat Stromal Cell Derived Factor-1 (SDF-1): SDF-1 $\alpha$ mRNA Is Selectively Induced in Rat Model of Myocardial Infarction", Inflammation, 25(5): 293-300, 2001. Abstract.			
	23	Redfield "Heart Failure - An Epidemic of Uncertain Proportions", New England Journal of Medicine, 347(18): 1442-1444, 2002. Abstract.			
	24	Saavedra et al. "Reverse Remodeling and Enhancedadrenergic Reserve From Passive External support in Experimental Dilated Heart Failure", Journal of the American College of Cardiology, JACC, 39(12): 2069-2076, 2002.			
	25	Salcedo et al. "Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Induce Expression of CXCR4 on Human Endothelial Cells. In Vivo Neovascularization Induced by Stromal-Derived Factor-1 $\alpha$ ", American Journal of Pathology, 154(4): 1125-1135, 1999.			
	26	Salisbury et al. "Influence of Coronary Artery Pressure Upon Myocardial Elasticity", Circulation Research, VIII: 794-800, 1960.			
	27	Salvucci et al. "Regulation of Endothelial Cell Branching Morphogenesis by Endogenous Chemokine Stromal-Derived Factor-1", Blood, 99(8): 2703-2711, 2002.			
	28	Schwarz et al. "Evaluation of Cardiac Structures and Function in Small Experimental Animals: Transthoracic, Transesophageal, and Intraventricular Echocardiography to Assess Contractile Function in Rat Heart", Basic Research in Cardiology, 93(6): 477-486, 1998. Abstract.			
	29	Tachibana et al. "The Chemokine Receptor CXCR4 Is Essential for Vascularization of the Gastrointestinal Tract", Nature, 393: 591-594, 1998. Abstract.			
	30	Watanabe et al. "Cardiomyocyte Transplantation in A Porcine Myocardial Infarction Model", Cell Transplantation, 7(3): 239-246, 1998. Abstract.			
Examiner Signature				Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\* EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document by the two-letter code (WIPO Standard ST 3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number.

<sup>6</sup> A direct translation should be made if English is not the language of the original document.

Applicant is to place a check mark here if English language translation is attached.  
This application of information is required by 23 CFR 1.97 and 1.98. The information

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to lie (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450